TY  - CHAP
M1  - Book, Section
TI  - Primary VTE Prevention & Treatment in Severe COVID-19
A1  - Leavitt, Andrew D.
A1  - Price, Erika Leemann
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
A2  - McQuaid, Kenneth R.
Y1  - 2023
N1  - 
T2  - Current Medical Diagnosis & Treatment 2023
AB  - Key  Clinical  Updates  in  Primary  VTE  Prevention  &  Treatment  in  Severe  COVID-19Therapeutic  dosing  of  anticoagulation  may  benefit  some  patients  who  are  hospitalized  in  the  acute  care  setting  with  COVID-19,  who  have  very  elevated  D-dimer  values  and  require  supplemental  oxygen,  and  who  have  low  bleeding  risk.Patients  who  are  critically  ill  in  ICUs  have  not  been  shown  to  benefit  from  therapeutic  dosing.There  is  no  clear  benefit  from  VTE  prophylaxis  for  patients  with  COVID-19  who  do  not  require  hospitalization.ATTACC  Investigators;  ACTIV-4a  Investigators;  REMAP-CAP  Investigators;  Lawler  PR  et  al.  N  Engl  J  Med.  [PMID:  34351721]REMAP-CAP  Investigators;  ACTIV-4a  Investigators;  ATTACC  Investigators;  Goligher  EC  et  al.  N  Engl  J  Med.  [PMID:  34351722]Spyropoulos  AC.  JAMA  Intern  Med.  [PMID:  34617959]  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/16
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1193159068
ER  -